ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,149.27
0.79%
Dow Jones
43,870.35
1.06%
Gold vs US Dollar
2,669.905
0.66%
Brent Oil
73.865
1.41%
Bitcoin
97,873.34
3.72%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Uniqure Nv (0EE0) Share Price

0EE0 Uniqure Nv

31.50
0.00 (0.00%)
21 Nov 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Uniqure Nv LSE:0EE0 London Stock Exchange Ordinary Share NL0010696654 UNIQURE ORD SHS
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.00 0.00 31.50 0.00 0.00 0.00 0.00  1,369 00:00:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations 21.9M -308.48M -6.4489 -0.91 1.51B
 Type  Size  Price  Time  Units 
  1 5.8786 18:45:34 USD
 
Recent News
DateTimeSource
HeadlineMore 0EE0 News
21/11/202412:05UKREGuniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
05/11/202412:05UKREGuniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
15/10/202411:05UKREGuniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
23/09/202411:05UKREGuniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
15/08/202411:05UKREGuniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
01/08/202411:05UKREGuniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
23/07/202411:05UKREGuniQure Announces Closing of Sale of Manufacturing Facility to Genezen
Period
Draw mode
Data Downloads for 0EE0

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)
Technical Analysis for Uniqure Nv
Get quick technical analysis for Uniqure Nv.
Price Indicators
Evaluate in real-time the trend for this stock with base on twelve different studies.
Candlesticks
Verify the trend for the closing and opening times for this stock or defined reversal patterns.
Support & Resistance
Automatically plot the main lines for support and resistance for this tock highlighting the main levels.


Loading Follow Feed...

Latest Uniqure Nv Articles

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Level 2 Lite

1 year 40%, 2 years 50% and *3 years 60%
EU Flag

*Across 3 years £2132.64 only £853.06